Iron-crosslinked Rososome with robust stability and high drug loading for synergistic cancer therapy

Xiangdong Xue, Marina Ricci, Haijing Qu, Aaron Lindstrom, Dalin Zhang, Hao Wu, Tzu Yin Lin, Yuanpei Li

Research output: Contribution to journalArticlepeer-review

Abstract

Development of liposomal nanomedicine with robust stability, high drug loading and synergistic efficacy is a promising strategy for effective cancer therapy. Here, we present an iron-crosslinked rosmarinic liposome (Rososome) which can load high contents of drugs (including 25.8% rosmarinic acid and 9.04% doxorubicin), keep stable in a high concentration of anionic detergent and exhibit synergistic anti-cancer efficacy. The Rososomes were constructed by rosmarinic acid-lipid conjugates which not only work synergistically with doxorubicin by producing reactive oxygen species but also provide catechol moieties for the iron cross-linkages. The cross-linkages can lock the payloads tightly, endowing the crosslinked Rososome with better stability and pharmacokinetics than its non-crosslinked counterpart. On the syngeneic mouse model of breast cancer, the iron-crosslinked Rososomes exhibit better anticancer efficacy than free rosmarinic acid, doxorubicin, non-crosslinked Rososome and commercial liposomal formulation of doxorubicin (DOXIL). This study introduces a novel strategy for the development of liposomes with robust stability, high drug loading and synergistic anti-cancer efficacy.

Original languageEnglish (US)
JournalJournal of Controlled Release
DOIs
StateAccepted/In press - 2020

Keywords

  • Chemotherapy
  • Crosslink
  • Drug delivery
  • Liposome
  • Synergistic effect

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Iron-crosslinked Rososome with robust stability and high drug loading for synergistic cancer therapy'. Together they form a unique fingerprint.

Cite this